Vertex Pharmaceuticals has announced that as of 1 July, the funding of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) will be expanded on the PBS to include around 45 additional patients with cystic fibrosis.
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News -
US announces formal plan that benchmarks pricing against Australia and 18 other countries
October 1, 2026 - -
Sandoz leads pharma's best workplaces as Rare Cancers Australia makes healthcare list
October 1, 2026 - - Latest News -
Eczema patients who don't respond to steroids get subsidised access to ointment
October 1, 2026 - - Latest News -
By the TGA's own test, the Health Minister's press releases are advertising
October 1, 2026 - - Latest News -
The regulator that deleted the truth from its answers now wants to police the media
October 1, 2026 - - Latest News
